Article
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer.
Nature - 1 Jul 2026
Lu Xiaocui, Wang Xiuyun, Yang Zheng, Wang Xusheng, Wang Lin, Xu Chunhui, Lo I-Chung, Geng Chenlu, Wang Lin, Pu Yisheng, Zhang Keyu, Zhu Ziqiang, Ye Lanxin, Huang Jiayuan, Wei Xiaofan, Bai Fang, Zhu Yanan, Qian Xiaobing, Dou Hao, Su Hexiu, Cang Yong
Abstract excerpt
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.